You are here

Funding

Duke CFAR Funding Opportunities

Dr. Gunn's Funding Newsletter - September 30, 2019

HIV Vaccine Research Grants for Medical Students
Seeking African American/Black and Latino/a medical students interested in HIV vaccine research

Please follow this link for more information!

 

NIAID New Innovator PAR for post-doctoral fellows

As part of the NIAID commitment to increase opportunities for post-doctoral fellows, the NIAID New Innovator Award (DP2), PAR-19-296, was published last week. The purpose is to support post-doctoral investigators of exceptional creativity who propose highly innovative bold new research with the potential to produce a major impact on broad, important problems in biomedical research relevant to the mission of NIAID. Applicants approved for funding would have one year to secure an independent, tenure-track (or equivalent) faculty position at an U.S. extramural institution to activate the award.  Through this initiative, NIAID wants to encourage shorter post-doctoral fellowships and provide the opportunity for creative scientists with little to no preliminary data to start their independent careers earlier. NIAID intends to award up to 10 applications per year.
 
Please share this FOA with any talented non-independent postdocs (research and/or clinical doctorate degree, U.S. or non-U.S. citizens), as well as with investigators who may know of appropriate candidates. The next receipt date is Oct 10, 2019 (once per year); clinical trials are not allowed for this FOA. The DAIDS contact for this PAR is Diane Lawrence.  Her contact info is below:
 
Diane Lawrence, Ph.D.
Program Officer, Pathogenesis and Basic Research Branch
Basic Science Program, Division of AIDS, NIAID
5601 Fishers Lane, Rm 9G22
Bethesda, MD 20892
240-627-3202, lawrencedi@niaid.nih.gov

 

2019 Adelante RFA

The NIH has opened the 2019 Adelante RFA. Adelante - meaning forward or onward in Spanish - embodies the primary mission of this mentored research program. Through Adelante, the Centers for AIDS Research strive to develop early-career investigators who focus on HIV/AIDS treatment, prevention, and care in the Latino/Hispanic community.

In this program, co-administered through the District of Columbia and Emory CFARs, the National Institutes of Health (NIH)-funded Centers for AIDS Research (CFARs) will support 2-year Adelante Team projects that include a 4 month Research Preparation period followed by a Research Implementation period of approximately 20 months. The goals of the program are to decrease HIV-related health disparities in the Hispanic/ Latino community and to promote the mentored development of new investigators to focus on HIV/AIDS in Hispanic/Latino populations.

Each CFAR Adelante Team will consist of a Principal Investigator (PI)/ Scholar, a CFAR Mentor, and a Collaborating Partner, who each meet the eligibility criteria.  Proposed research should be community based and reflect local Hispanic/Latino-community needs, as identified by science and the local community. Research proposal topics may include but are not limited to: 

  • Health disparities in the incidence of new HIV infections or in treatment outcomes of those living with HIV/AIDS.
  • Studies that examine factors that increase HIV risk in diverse Hispanic populations;
  • The cause of disparate outcomes of HIV infection and factors that influence pathogenesis in Hispanic populations;
  • Factors driving the social stigmatization of HIV in the Hispanic/Latino community;
  • Pilot interventions to engage faith-based organizations in the effective promotion of stigma reduction, HIV prevention promotion, HIV testing, timely linkage to HIV/AIDS care, and/or participation in research for experimental AIDS vaccines, biomedical prevention interventions, and treatment regimens;
  • Interventions to increase the frequency of HIV testing in Latino/Hispanic populations, timely linkage to care, earlier treatment initiation, better adherence to regimens, improved retention in care, and/or viral suppression;
  • Developing or testing novel, culturally-sensitive interventions for care coordination, particularly those that take a comprehensive approach to co-morbid medical and social service needs;
  • Behaviors after a negative HIV test (e.g., repeat HIV-testing, partner communication, use of PrEP or other prevention strategies), particularly in vulnerable and high risk Latino/Hispanic sub-populations such as drug users, sex workers, partners of HIV+ individuals, and young men who have sex with men;
  • Development and testing of culturally-responsive interventions to optimize repeat HIV testing, including interventions that reach individuals using technology (e.g., social media, messaging, applications on hand-held devices).

Applicants may request up to $75,000 (direct costs) per year, plus applicable indirect costs, not to exceed $150,000 in total costs per year. This funding may be used for salaries, technical support, laboratory supplies, equipment, enrollment in training classes or workshops, travel to the CFAR Mentor's institution, or other research or training-related activities.

You can find more details and the full RFA at the Adelante website here.

 

Food as Medicine: Food Insecurity and HIV-related Comorbidities, Coinfections, and Complications within the Mission of the NIDDK (R01 Clinical Trial Optional)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Purpose:  This funding opportunity announcement (FOA) seeks US domestic research projects that address how food insecurity effects   HIV comorbidities, coinfections, and complications (CCCs) within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions that alleviate food insecurity improve CCCs. These mechanisms could be related to nutritional inadequacies or patient health-related behaviors.
  • Open Date: February 09, 2020
  • Amount of Award: NIDDK intends to commit $2,000,000 in FY 2021 to fund 4-5 awards. Application budgets are limited to $500,000 direct costs per year and need to reflect the actual needs of the proposed project.
  • Due Date: March 9, 2020, by 5:00 PM local time of applicant organization
  • More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-019.html
  • End Date: March 10, 2020

 

Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), Fogarty International Center (FIC), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Cancer Institute (NCI)
  • Purpose: The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or caregivers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).
  • Open Date: October 12, 2019
  • Amount of Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $150,000 may be requested in any single year. The budget request must reflect the actual needs of the proposed project.
  • Due Date: November 12, 2019, November 12, 2020  by 5:00 PM local time of applicant organization
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-19-326.html
  • End Date: November 13, 2020

 

Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

  • Participating Organization(s) and Components:  National Institutes of Health (NIH), National Cancer Institute (NCI)
  • Purpose: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention.
    Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.
    This FOA is patterned on, but unrelated to, a series of FOAs for “Research Answers to NCI’s Provocative Questions".
  • Open Date: July 1, 2019
  • Amount of Award: NCI intends to commit $4,000,000 in FY 2021 to fund 6-8 awards.
  • Due Date: August 1, 2019; August 3, 2020, by 5:00 PM local time of applicant organization.
  • More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-032.html
  • End Date: August 4, 2020

 

High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)

 

Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01 Clinical Trial Optional)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Purpose: HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiative seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Multiple factors need to be investigated, including potentially important patient and provider characteristics, and the organizational, financial, and structural factors that facilitate or inhibit the delivery of evidence-based services for HIV+ individuals with a range of severity of alcohol use problems. The overall goal is to inform clinical decision-making to implement effective interventions that will improve prevention, care, and outcomes across the continuum of HIV and alcohol problem severity and patterns of alcohol use. This solicitation is divided into two major topics. An application may choose to address one or both. These topics include: 1) comparative effectiveness research focused on understanding factors related to early detection, patient engagement and retention in appropriate alcohol and HIV care, and achieving and maintaining optimal treatment responses in diverse settings, and 2) modeling and testing alternative implementation approaches to improve uptake and scaling-up of effective interventions and reduce HIV disease transmission and progression.
  • Open Date: January 5, 2018
  • Amount of Award: NIH intends to fund an estimate of 4-6 awards, corresponding to a total of $3 million per year, for fiscal year 2018 to 2022.
  • Due Date: Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. 
    Standard AIDS dates apply), by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAS-18-557.html
  • End Date: May 8, 2020

 

Detection of HIV for Self-Testing (R61/R33)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support bi-phasic developmental, discovery-driven, or hypothesis-driven research focused on innovative strategies to detect HIV either within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy. Applications should propose simple diagnostic tools that would be feasible for a self-testing platform to allow untrained individuals to detect HIV. Interdisciplinary collaborations that include biomedical, physical, and behavioral sciences are highly encouraged.    
  • Open Date: November 6, 2017
  • Amount of Award: NIAID intends to commit $2,640,000 in FY 2018 to fund 3-6 awards. NIMH intends to commit $300,000 total cost in FY 2018.  Future year amounts will depend on annual appropriations. 
  • Due Date: December 6, 2017, December 6, 2018, and December 6, 2019 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
    December 6, 2017, December 6, 2018, and December 6, 2019, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-17-471.html
  • End Date: December 7, 2019

 

Apply now for the UCSF CAPS Visiting Professors Program

The UCSF Center for AIDS Prevention Studies (CAPS) has a Visiting Professors program to train investigators in conducting research with ethnic minority communities. The VP Program is designed to assist investigators already conducting HIV-prevention research with minority communities to improve their programs of research and obtain additional funding for their work. It includes a 6-week summer residency, pilot funding, and other mentorship and career development opportunities. More information is described below and at their website: http://vp.ucsf.edu/.